Add Yahoo as a preferred source to see more of our stories on Google. A number of radiopharmaceutical drug developers use a synthetic isotope of the chemical element lutetium. (Lark Andrew Balcita via ...

Garching / Munich, Germany, November 10, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in upcoming industry investor ...

Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimusGarching / Munich, July 7, 2026- ITM Isotope ...

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimus ITM plans ...

¹⁷⁷Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotide Data build upon previously reported COMPETE ...

ITM Isotope Technologies has provided more detail on how its lead radiotherapy bested the standard of care in a recent phase 3 study while revealing that the candidate was unable to prove a ...

Patient enrollment has been completed; all enrolled patients remain alive Data presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany ...

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within ...

BlackRock Alternatives and Nextech invested in ITM Isotope Technologies thanks to the company’s unique position in the burgeoning radiopharmaceuticals market, the firms told PE Hub Europe.

ITM Isotope Technologies Munich, a German radiopharmaceutical biotechnology company, has secured a €33 million ($36 million) investment. The investors were Indigenous Critical Infrastructure Fund ...